two
die
studi
confi
rmed
case
ontario
canada
cough
fever
sore
throat
gastrointestin
symptom
report
patient
respect
hospit
rate
case
fatal
ratio
patient
sever
diseas
present
fever
cough
dyspnea
respiratori
distress
increas
serum
lactat
dehydrogenas
level
bilater
patchi
pneumonia
fig
c
common
fi
nding
increas
creatinin
kinas
level
lymphopenia
outlin
warn
sign
sever
diseas
list
tabl
although
sever
diseas
may
occur
otherwis
well
young
subject
often
risk
factor
develop
sever
diseas
tabl
contrast
season
infl
uenza
sever
pandem
diseas
relat
mortal
occur
among
children
adult
age
year
wherea
patient
requir
hospit
die
previous
healthi
number
icu
admiss
due
pandem
infect
time
number
due
viral
pneumon
recent
year
australia
new
zealand
elderli
year
less
frequent
infect
novel
viru
probabl
preexist
crossreact
immun
viru
due
past
exposur
previou
circul
season
infl
uenza
strain
similar
current
pandem
viru
howev
controversi
season
infl
uenza
vaccin
antigen
compon
confer
crossimmun
pandem
strain
autopsi
fi
nding
shown
three
distinct
pulmonari
histolog
pattern
diffus
alveolar
damag
necrot
bronchiol
diffus
alveolar
damag
intens
alveolar
hemorrhag
also
evid
ongo
pulmonari
aberr
immun
respons
pulmonari
emboli
note
wherea
secondari
bacteri
fungal
pneumonia
report
fatal
case
california
fatal
case
coinfect
communityacquir
methicillinresist
staphylococcu
aureu
mrsa
occur
filipino
sailor
die
hong
kong
studi
american
patient
fatal
case
confi
rmed
pandem
infect
evid
concurr
bacteri
infect
found
patient
includ
streptococcu
pneumonia
six
streptococcu
pyogen
seven
aureu
two
streptococcu
miti
one
haemophilu
infl
uenza
four
case
involv
multipl
pathogen
median
age
patient
year
median
durat
ill
day
fi
nding
confi
rm
bacteri
lung
infect
occur
among
patient
fatal
case
pandem
infect
underscor
need
earli
recognitiontreat
bacteri
pneumonia
patient
infl
uenza
global
popul
becam
infect
half
suffer
clinic
ill
pandem
occur
caus
death
unit
state
anoth
new
type
emerg
remain
circul
today
pandem
infl
uenza
new
strain
infl
uenza
viru
fi
rst
identifi
ed
mexico
unit
state
march
april
respect
pandem
viru
origin
triplereassort
swine
infl
uenza
viru
circul
north
american
pig
complet
genom
sequenc
shown
known
molecular
marker
pathogen
protein
express
pandem
viru
anim
studi
shown
novel
infl
uenza
viru
caus
increas
morbid
replic
higher
titer
lung
tissu
recov
intestin
tract
intranas
inocul
ferret
contrast
season
infl
uenza
viru
may
explain
novel
viru
rel
pathogen
season
infl
uenza
virus
capac
invad
lower
respiratori
tract
caus
rapidli
progress
pneumonia
human
lack
background
immun
former
within
sever
week
onset
novel
viru
spread
throughout
world
intern
air
travel
result
infl
uenza
pandem
world
health
organ
rais
level
infl
uenza
pandem
alert
phase
phase
sinc
june
novemb
laboratoryconfi
rmed
case
pandem
death
countri
territori
report
countri
stop
count
individu
case
particularli
milder
ill
case
count
signifi
cantli
lower
actual
number
case
occur
major
patient
pandem
infect
develop
mild
upper
respiratori
tract
symptom
similar
season
infl
uenza
gastrointestin
symptom
seem
common
former
studi
confi
rmed
case
earli
outbreak
unit
state
april
patient
year
age
among
avail
data
histori
recent
travel
mexico
wherea
identifi
ed
school
outbreak
common
present
symptom
fever
cough
sore
throat
patient
diarrhea
vomit
patient
hospit
statu
known
requir
hospit
import
pneumococc
vaccin
person
increas
risk
pneumococc
pneumonia
indic
hospit
list
tabl
nasal
swab
nasal
secret
anterior
turbin
area
nasopharyng
aspir
swab
appropri
specimen
detect
human
infl
uenza
b
although
rapid
infl
uenza
diagnost
test
capabl
detect
novel
viru
respiratori
specimen
contain
high
level
viru
overal
sensit
low
among
specimen
test
declin
substanti
viru
level
decreas
patient
ill
compat
pandem
viru
infect
neg
rapid
infl
uenza
diagnost
test
result
treat
empir
base
level
clinic
suspicion
underli
medic
condit
sever
ill
risk
complic
defi
nitiv
determin
infect
infl
uenza
viru
requir
test
realtim
revers
transcriptionpolymeras
chain
reaction
rtpcr
viru
isol
perform
patient
requir
invas
mechan
ventil
imv
tracheal
aspir
may
offer
higher
diagnost
yield
nasopharyng
flock
swab
fig
sequenti
sampl
import
increas
opportun
posit
diagnosi
facilit
understand
viral
loadclear
ill
cours
addit
monitor
develop
antivir
resist
pandem
viru
current
suscept
neuraminidas
inhibitor
resist
matrix
inhibitor
patient
infect
pandem
viru
experi
typic
infl
uenza
symptom
fulli
recov
within
week
even
without
form
medic
treatment
healthi
patient
uncompl
ill
need
treat
antivir
patient
initi
present
sever
ill
whose
condit
begin
deterior
treatment
oseltamivir
commenc
soon
possibl
antivir
treatment
provid
even
start
later
h
oseltamivir
unavail
use
reason
zanamivir
may
given
recommend
appli
patient
group
includ
pregnant
women
age
group
includ
young
children
infant
food
drug
administr
unit
state
approv
emerg
use
intraven
peramivir
treatment
sever
case
wherea
zanamivir
dri
powder
administ
nebul
risk
resist
consid
higher
patient
sever
compromis
suppress
immun
system
prolong
ill
receiv
oseltamivir
treatment
especi
extend
durat
still
evid
persist
viral
replic
risk
resist
also
consid
higher
peopl
receiv
oseltamivir
postexposur
prophylaxi
follow
exposur
anoth
person
infl
uenza
develop
ill
despit
take
oseltamivir
gener
recommend
use
antivir
drug
prophylact
purpos
altern
option
close
monitor
symptom
peopl
exposur
infect
person
higher
risk
develop
sever
complic
ill
follow
prompt
earli
antivir
treatment
symptom
develop
respiratori
support
critic
ill
patient
patient
clinic
ill
due
novel
infect
requir
hospit
overal
case
fatal
ratio
estim
rapidli
progress
respiratori
failur
rel
common
hospit
patient
requir
icu
admiss
imv
lungprotect
ventil
strategi
recommend
initi
approach
manag
patient
pandem
infect
complic
ard
recommend
base
ardsnet
trial
demonstr
rel
risk
reduct
mortal
patient
ard
ventil
lower
tidal
volum
eg
goal
maximum
tidal
volum
mlkg
predict
bodi
weight
plateau
pressur
maximum
cm
h
furthermor
prudent
adopt
conserv
fl
uid
manag
approach
patient
ardsacut
lung
injuri
shown
increas
ventilatorfre
day
improv
oxygen
compar
fl
uid
liber
strategi
icu
expertis
technolog
avail
extracorpor
membran
oxygen
ecmo
highfrequ
oscil
ventil
prone
posit
inhal
nitric
oxid
report
use
rescu
therapi
critic
ill
patient
lactos
sugar
formul
obstruct
proper
function
mechan
ventil
equip
patient
underli
medic
condit
increas
risk
sever
diseas
recommend
treatment
either
oseltamivir
zanamivir
soon
possibl
symptom
onset
without
wait
result
laboratori
test
sever
case
global
occur
previous
healthi
children
adult
usual
age
year
patient
experi
sudden
rapid
deterior
clinic
condit
usual
day
follow
onset
symptom
clinic
deterior
character
primari
viral
pneumonia
failur
multipl
organ
includ
heart
kidney
liver
patient
requir
manag
icu
case
sever
deterior
ill
clinician
may
consid
use
higher
dose
oseltamivir
longer
durat
eg
mg
bid
day
adult
normal
prescrib
case
oseltamivirresist
virus
continu
sporad
infrequ
evid
oseltamivirresist
pandem
virus
circul
within
commun
worldwid
virus
show
nomenclatur
mutat
confer
resist
antivir
oseltamivir
antivir
zanamivir
thu
zanamivir
remain
treatment
option
symptomat
patient
sever
deterior
ill
due
oseltamivirresist
viru
care
includ
nppv
among
aerosolgener
procedur
possibl
increas
risk
respiratori
pathogen
transmiss
lowdos
heparin
start
prophylact
critic
ill
patient
requir
icu
treatment
view
report
pulmonari
embol
especi
among
critic
ill
obes
patient
pandem
infect
highdos
corticosteroid
shown
benefi
cial
ard
septic
shock
unrel
viru
infect
reduc
mortal
howev
stressdos
corticosteroid
hydrocortison
mgd
may
benefi
cial
improv
hospit
mortal
morbid
outcom
although
lowdos
corticosteroid
may
consid
manag
refractori
septic
shock
precis
role
system
steroid
set
ard
refractori
shock
due
sever
infl
uenza
pneumon
requir
investig
metaanalys
date
mainli
deriv
data
relat
bacterialinduc
median
durat
imv
day
ventil
patient
sever
respiratori
failur
australia
new
zealand
receiv
ecmo
support
surviv
rate
subgroup
overal
icu
mortal
rate
critic
ill
case
close
factor
independ
associ
death
hospit
includ
requir
imv
icu
admiss
coexist
condit
older
age
noninvas
posit
pressur
ventil
nppv
appli
small
number
critic
ill
patient
pandem
infect
complic
respiratori
failur
patient
subsequ
requir
imv
support
nppv
gener
recommend
patient
novel
infl
uenza
infect
complic
pneumonia
ard
nppv
temporarili
improv
oxygen
reduc
work
breath
necessarili
alter
cours
diseas
need
nppv
indic
sever
diseas
likelihood
imv
addit
hemodynam
instabl
multiorgan
failur
contraind
applic
nppv
interim
guidelin
prevent
control
acut
respiratori
diseas
health
metaanalysi
suggest
earli
administr
convalesc
blood
product
might
reduc
risk
death
patient
spanish
infl
uenza
pneumonia
pandem
convalesc
plasma
use
rescu
therapi
seemingli
favor
respons
male
patient
sever
infect
complic
multiorgan
failur
despit
treatment
oseltamivir
although
diffi
cult
judg
effi
caci
convalesc
plasma
without
random
control
studi
howev
experiment
evid
anim
model
administr
c
antibodi
form
neutral
monoclon
antibodi
polyclon
sera
convalesc
postimmun
effect
treat
infl
uenza
diseas
thu
passiv
immunotherapi
includ
form
hyperimmun
globulin
made
convalesc
plasma
potenti
option
treatment
pandem
infect
high
viral
load
result
intens
infl
ammatori
respons
hypothes
caus
organ
damag
sever
morbiditymort
diseas
cytokin
dysregul
also
invok
pathogenesi
sepsi
septic
shock
statin
antiinfl
ammatori
immunomodulatori
effect
eg
repress
induct
major
histocompat
complexii
interferong
subsequ
tlymphocyt
activ
statin
propos
play
potenti
role
treatment
prophylaxi
pandem
infl
uenza
base
observ
studi
show
surviv
benefi
ts
patient
receiv
statin
develop
bacteremia
sepsi
pneumonia
balbc
mice
g
g
caffein
effect
amelior
lung
damag
inhibit
viral
replic
least
effect
oseltamivir
ribavirin
statinscaffein
combin
also
appear
effect
administ
prevent
rather
treatment
fi
nding
provid
justifi
cation
research
novel
antivir
formul
iv
ig
may
consid
treatment
option
immunomodul
effect
infl
uenza
activ
system
infl
ammat
iv
ig
use
treatment
sar
thromboembol
event
sepsi
data
specifi
c
pandem
limit
import
use
system
corticosteroid
caution
treatment
respiratori
viral
diseas
earli
use
corticosteroid
might
prolong
viral
replic
sever
acut
respiratori
syndrom
sar
infl
uenza
addit
prolong
use
system
corticosteroid
sar
led
sever
advers
effect
includ
fatal
dissemin
aspergillu
infect
osteonecrosi
sar
period
icu
use
system
steroid
associ
increas
rate
isol
mrsa
stenotrophomona
candida
speci
ventilatorassoci
pneumonia
rate
high
episod
per
ventilatorday
episod
caus
mrsa
mrsa
acquisit
rate
also
increas
presar
period
sar
period
use
system
steroid
acut
exacerb
copd
due
pandem
infect
may
potenti
prolong
viral
shed
fig
vide
routin
care
patient
infect
pandem
infl
uenza
infl
uenzalik
symptom
recent
data
suggest
surgic
mask
effect
mask
respiratori
protect
hcw
routin
care
hospit
patient
season
infl
uenza
also
import
limit
number
hcwsfamili
membersvisitor
expos
patient
pandem
addit
implement
triag
earli
recognit
report
pandem
infect
addit
import
monitor
health
hcw
expos
patient
pandem
wherea
hcw
symptom
stay
home
vulner
group
high
risk
complic
pandem
infect
care
follow
recommend
infectioncontrol
measur
addit
altern
reassign
duti
consid
antivir
prophylaxi
follow
local
polici
perform
aerosolgener
procedur
eg
aspir
respiratori
tract
intub
resuscit
bronchoscopi
autopsi
hcw
awar
procedur
associ
increas
risk
infect
transmiss
upgrad
airborn
infect
control
precaut
includ
use
mask
tabl
import
note
substanti
exposur
exhal
air
occur
within
radiu
patient
receiv
oxygen
therapi
via
hudson
mask
applic
nppv
respect
geograph
target
nonpharmacolog
measur
earli
case
isol
household
quarantin
schoolworkplac
closur
restrict
travel
use
measur
control
infl
uenza
pandem
earli
phase
pandem
vaccin
import
strategi
control
pandem
diseas
effi
caci
modal
limit
shortag
suppli
due
limit
product
capac
vaccin
avail
soon
enough
estim
vaccin
children
follow
adult
reach
overal
coverag
addit
highrisk
essenti
workforc
group
could
mitig
sever
epidem
pulmonari
embol
ischem
stroke
despit
use
prophylact
lowmolecularweight
heparin
thu
import
monitor
complic
iv
ig
especi
vascular
thrombot
event
product
reactiv
oxygen
speci
ro
shown
contribut
pulmonari
damag
caus
infl
uenza
viru
infect
differ
sourc
ro
suggest
infl
uenza
virusinfect
lung
leukocyt
may
activ
prime
infl
uenza
viru
infect
produc
ro
moreov
increas
xanthin
oxidas
level
found
infl
uenza
virusinfect
lung
epitheli
cell
lung
may
also
sourc
ro
sinc
infl
uenza
viru
infect
induc
oxid
stress
respons
cultur
airway
epitheli
cell
antioxid
n
acetyl
cystein
nac
shown
inhibit
replic
season
human
infl
uenza
virus
nac
inhibit
replic
product
proinfl
ammatori
molecul
therefor
antioxid
like
nac
repres
potenti
addit
treatment
option
could
consid
case
sever
infl
uenza
infect
compound
immunomodul
properti
macrolid
gemfi
brozil
glitazon
nutrit
supplement
propos
adjunct
treatment
would
requir
investig
control
clinic
trial
infect
control
lesson
sar
import
clinic
implic
infect
control
human
infl
uenza
pandem
casecontrol
studi
involv
medic
ward
hospit
guangzhou
hong
kong
identifi
ed
six
independ
risk
factor
superspread
nosocomi
outbreak
sar
minimum
distanc
bed
perform
resuscit
staff
work
experi
symptom
sar
patient
requir
oxygen
therapi
nppv
wherea
avail
wash
chang
facil
staff
protect
factor
good
hand
respiratori
hygien
led
signifi
cant
reduct
common
respiratori
viral
infect
commun
hong
kong
sever
measur
recommend
context
pandem
epidem
includ
maintain
standard
droplet
precaut
among
healthcar
worker
hcw
level
health
care
emphas
respiratori
etiquett
hand
hygien
cohort
adequ
room
ventil
separ
minimum
distanc
patient
pro
perform
aerosolgener
procedur
wear
facial
particul
respir
eg
eu
us
nioshcertifi
ed
eye
protect
ie
goggl
face
shield
clean
nonsteril
longsleev
gown
glove
procedur
requir
steril
glove
perform
procedur
adequ
ventil
room
air
chang
per
h
avoid
permit
unnecessari
individu
room
perform
hand
hygien
patient
contact
remov
person
protect
equip
prioriti
group
receiv
pandem
vaccin
list
tabl
pandem
viru
new
nonclin
clinic
trial
conduct
gain
essenti
inform
immun
respons
safeti
outcom
trial
complet
date
suggest
pandem
vaccin
safe
season
infl
uenza
vaccin
advis
countri
administ
pandem
vaccin
conduct
intens
monitor
safeti
report
advers
event
summari
antivir
agent
pandem
vaccin
import
modal
control
pandem
efficaci
limit
time
administr
suppli
oxygen
therapi
nppv
appli
healthcar
facil
good
ventil
respiratori
protect
hcw
patient
sever
respiratori
failur
requir
imv
lungprotect
ventil
strategi
conserv
fl
uid
manag
approach
recommend
patient
ard
rescu
therapi
includ
ecmo
may
consid
applic
standard
icu
manag
practic
lowdos
system
steroid
may
consid
patient
refractori
septic
shock
role
passiv
immunotherapi
immunomodul
agent
iv
ig
statin
gemfi
brozil
nac
requir
investig
nonpharmacolog
measur
earli
case
isol
household
quarantin
school
workplac
closur
good
commun
hygien
restrict
travel
use
measur
control
infl
uenza
pandem
earli
phase
